Literature DB >> 24738958

Oral chemotherapy in elderly women with metastatic breast cancer.

M J Molina-Garrido, A Mora-Rufete, C Guillen-Ponce1.   

Abstract

Life expectancy has significantly increased over the past 30 years, with a greater prevalence of diverse disease states, especially cancer. As older persons are a very heterogeneous group with an increased prevalence of comorbidities and a relative inability to tolerate the adverse effects of chemotherapy, the treatment of cancer in the elderly is particularly demanding. The principles of its management are similar to those in younger patients but with special considerations linked to comorbidities and clinical status. The objective of chemotherapeutic treatment in metastatic breast cancer has historically been primarily palliative. The introduction of newer approaches with improved or at least equivalent efficacy and reduced toxicity is highly desirable. Such approaches may include the use of less toxic drugs, more convenient routes of administration (e.g., oral) and home-based (outpatient) rather than hospital-based therapies. The available oral cytostatic drugs include vinorelbine and capecitabine. In this review, we analyze oral cytostatic drugs in the elderly patient diagnosed with metastatic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24738958     DOI: 10.2174/1871520614666140416103440

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer.

Authors:  Huimin Lv; Min Yan; Mengwei Zhang; Limin Niu; Huiai Zeng; Shude Cui
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

2.  Care of the Elderly Patient on Oral Oncolytics for Advanced Disease.

Authors:  Charles W Given; Barbara A Given
Journal:  Curr Geriatr Rep       Date:  2016-07-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.